The Company's full financial statements and related MD&A for the first quarter ended September 30, 2024, are available at www.inmedpharma.com, www.sedar.com and at www.sec.gov.
Alzheimer’s changed the couple’s routine, but not their fight to keep going. Together, David and Pamela are awareness advocates for the Alzheimer’s Association. They’ve met with representatives on ...
Most discontinued anti-tau antibodies (red) targeted tau’s N-terminus. Of the antibodies currently in trials (green), bepranemab and E2814 presented results at CTAD, while JJ-63733657/posdinemab and ...
A European regulatory committee now recommends approval of the Alzheimer's treatment lecanemab a few months after rejecting ...
Researchers at Texas A&M University have developed a nasal spray shown to delay disease progression in animals -- fueling ...
A multitude of genes have been linked to the development of Alzheimer's disease. Specifically how those genes might influence ...
A breakthrough in the fight against Alzheimer’s disease may have been made in Seattle. Researchers at the Allen Institute ...
Along with an Alzheimer’s diagnosis comes a flood of questions, both for the person with the disease and their family. The uncertainty of a future with Alzheimer’s is ...
In the world of health, Novo Nordisk stops insulin pen production, Trump's potential health appointments draw attention, and ...
The European Union's drugs regulator reversed its decision to block the Alzheimer's drug lecanemab, a treatment aimed at ...
A key regulatory committee sided against the drug this summer. But an appeal from Eisai appears to have worked, teeing ...
The "Caring for the Caregiver" resource fair is designed to provide assistance and support for individuals facing challenges such as memory problems.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback